An interventional study of Intervention in Pregnancy, sponsored by Universidad Pública de Navarra. Enrolling by invitation at 1 site in Spain. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Universidad Pública de Navarra · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 597 studies in Motor Activity with a site in Spain — 148 open to participants now, 184 under way, 1 of them phase 3. Motor Activity · Spain.
Among the 597 studies in Motor Activity with a site in Spain, this one is the 312th largest by planned enrollment of the 539 interventional ones that give a count, is one of 77 that started in 2025, is one of 515 with no phase, reaches primary completion later than 160 of the 183 other live ones, and was the 509th registered.
9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.
Browse Motor Activity studies →148 of the 597 studies in Motor Activity with a site in Spain are open now. Recruiting first, the newest first:
Universidad Pública de Navarra · Sites in Spain
Ages 65+
University of Valencia · Sites in Spain
Ages 60–99
Universidad San Jorge · Sites in Spain
Ages 18–65 · Healthy volunteers
Institut Investigacio Sanitaria Pere Virgili · Sites in Spain
Ages 18+ · Women only
Alberto Bermejo Franco · Sites in Spain
Ages 70+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.
This study: 18 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
597 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 9 · Phase 4 4
First in 2004; this study’s year is marked. 77 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is close to the median of 60 across 8,412 interventional studies indexed under Motor Activity.
Median enrollment 80 across the 539 interventional studies, 145 across the 58 observational. Of the 335 that completed or were terminated, 5 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 597 have an industry lead sponsor. The 10 most frequent:
Universidad Pública de Navarra is the lead sponsor of 14 studies on the registry; 5 are open to participants now.
Universidad Pública de Navarra has 5 studies filed under Motor Activity — fewer than ten, so there is no comparison to draw.
47 of the studies in Motor Activity with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07183241Universidad Pública de NavarraHospital-to-Home Rehabilitation Through Exercise and Cognitive Training | 2026-12 |
| NCT07489391University of DeustoConcomitant Use of Radiotherapy and Integrated Exercise - Lung Cancer | 2026-12 |
| NCT07232511University of ValenciaExercise-induced Hypoalgesia Effects of Blood Flow Restriction in People With Rotator Cuff-related Shoulder Pain | 2026-12 |
| NCT06446596University of ValenciaTelerehabilitation-based Exercises vs Standard Home-based Exercise in Low Back Pain | 2026-12 |
| NCT06948500Cardenal Herrera UniversityEffectiveness of an IVR-based Therapeutic Exercise Program With Altered Visual Feedback in Fibromyalgia Patients | 2026-12-01 |
Add all 47 to your calendar (.ics) → With an account.
Among the 597 studies in Motor Activity with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Metabolic alterations during pregnancy have been associated with adverse maternal-fetal outcomes, including low birth weight and pregnancy complications. Maternal endothelial dysfunction, oxidative stress, insulin resistance, and placental mitochondrial dysfunction are thought to contribute to fetal metabolic disturbances. Lifestyle changes, such as structured exercise during pregnancy, may modulate maternal and placental factors.
This randomized controlled trial will evaluate the effects of a multicomponent exercise program during the second and third trimester on maternal functional capacity, vascular health, anthropometry, metabolic biomarkers, placental function, and newborn health outcomes.
To investigate the effects of a multicomponent supervised exercise program during pregnancy on the maternal-fetal unit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will perform a supervised aerobic exercise program at 70% of maximum heart rate (HRmax), for 45 minutes per session, 3 times per week, during 12 weeks. Each session will follow a standardized protocol: 10 minutes of warm-up, 30 minutes of aerobic exercise, 5 minutes of cool-down and stretching. In addition, strength training sessions will be included 1-2 times per week. All exercise sessions will be delivered by qualified professionals, including exercise specialists, nutritionists, and physiotherapists with \>3 years of experience and a master's-level education in the field. The intervention will be conducted at the Exercise Physiology Unit (E-FIT Group Laboratory), Navarrabiomed Research Center, Pamplona, Spain.
Behavioral: Intervention
Usual care as provided by the health services in Spain. The investigators will not advice the women to be inactive.
Exercise
Cardiorespiratory fitness (Vo2max)
The modified cycle protocol will be performed to estimate maximal oxygen uptake (VO2max), and will be used as measure of cardiorespiratory fitness.
Time frame: at the 16th and 34-36th week of gestation
Maternal weight gain (kg)
Maternal weight gain will be defined as the weight change from baseline measurement to the last measurement
Time frame: 34-36th week of gestation
Systolic and diastolic blood pressure (mmHg)
Systolic and diastolic blood pressure (mmHg) will be measured after 5 minutes of rest, on 2 separate occasions (with 2 minutes between trials), with the person seated (Omron Health Care Europe B.V. Hoolddorp). The lowest value of the two trials will be selected for the analysis.
Time frame: at the 16th and 34-36th week of gestation
Resting heart rate (bpm)
Resting heart rate (bpm), will be measured after 5 minutes of rest, on 2 separate occasions (with 2 minutes between trials), with the person seated (Omron Health Care Europe B.V. Hoolddorp). The lowest value of the two trials will be selected for the analysis.
Time frame: at the 16th and 34-36th week of gestation
Muscle strength (kg)
The handgrip strength and leg press test will be used as measure of strength (upper and lower limbs)
Time frame: at the 16th and 34-36th week of gestation
Whole bone mineral density (g/cm2)
Dual-energy X-ray absorptiometry (DXA) body composition measure
Time frame: at the 16th to 34-36th week of gestation
Fat free mass
Dual-energy X-ray absorptiometry (DXA) body composition measure
Time frame: at the 16th to 34-36th week of gestation
Lean mass/fat mass ratio
Dual-energy X-ray absorptiometry (DXA) body composition measure
Time frame: at the 16th to 34-36th week of gestation
Fat mass (kg)
Dual-energy X-ray absorptiometry (DXA) body composition measure
Time frame: at the 16th to 34-36th week of gestation
Fat mass index (kg/m2)
Dual-energy X-ray absorptiometry (DXA) body composition measure
Time frame: at the 16th to 34-36th week of gestation
Appendicular lean mass index (kg/m2)
Dual-energy X-ray absorptiometry (DXA) body composition measure
Time frame: at the 16th to 34-36th week of gestation
Lean mass index (kg/m2)
Dual-energy X-ray absorptiometry (DXA) body composition measure
Time frame: at the 16th to 34-36th week of gestation
Lean mass (kg)
Dual-energy X-ray absorptiometry (DXA) body composition measure
Time frame: at the 16th to 34-36th week of gestation
Physical activity and sedentary behaviour (in minutes)
Accelerometry will be used to objectively assess physical activity and sedentary time. Women will be asked to wear a tri-axial accelerometer (ActiSleep+, Pensacola, Florida, United States) for 5-7 consecutive days, starting the same day they receive the monitor (e.g. participants who receive the accelerometer on Monday, will carry the device until Tuesday of the next week).
Time frame: at the 16th and 34-36th week of gestation
Pittsburgh Sleep Quality Index
Accelerometry will be used to objectively assess physical activity and sedentary time. Women will be asked to wear a tri-axial accelerometer (ActiSleep+, Pensacola, Florida, United States) for 5-7 consecutive days, starting the same day they receive the monitor (e.g. participants who receive the accelerometer on Monday, will carry the device until Tuesday of the next week).
Time frame: at the 16th and 34-36th week of gestation
Quality of life (EQ-5D-5L)
We will use the EQ-5D-5L survey, for assessing health-related quality of life, ranging from 0 ("worst imaginable health state") to 100 ("best imaginable health state"), with higher scores representing better perceived health.
Time frame: at the 16th and 34-36th week of gestation
Epidemiological Studies-Depression Scale questionnaire
The pregnant antenatal depression levels will be assessed by the Center for Epidemiological Studies-Depression Scale questionnaire, which is validated and widely employed in pregnancy. The total score ranges from 0 to 60, with higher scores indicating more severe depressive symptoms.
Time frame: at the 16th and 34-36th week of gestation
Oswestry Disability Index score
Low-back pain will be assessed with the Spanish version of the Oswestry Disability Index (ODI) score. The final ODI score ranges from 0 to 100, where 0 represents no disability and 100 represents maximum disability.
Time frame: at the 16th and 34-36th week of gestation
Physical Activity index
Physical Activity will be assessed with the Spanish adaptation and validation of the Pregnancy Physical Activity Questionnaire (PPAQ). The scale ranges from 0 to 400+ MET·h/week, with higher scores indicating greater energy expenditure and physical activity levels.
Time frame: at the 16th and 34-36th week of gestation
Pain Visual Analogue Scale
General or specific pain intensity will also be assessed using the Pain Visual Analogue Scale (VAS), a validated self-reported measure of perceived pain intensity. The VAS consists of a 10-centimeter horizontal line anchored by "no pain" (0) and "worst imaginable pain" (10) at each end. Participants will indicate their current pain level by marking a point along the line, with higher scores representing greater pain intensity.
Time frame: at the 16th and 34-36th week of gestation
Cognitive Function
Global cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), a validated screening tool that evaluates multiple cognitive domains, including executive function, memory, attention, language, and visuospatial abilities. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.
Time frame: at the 16th and 34-36th week of gestation
Adherence to the Mediterranean Diet
Adherence to the Mediterranean dietary pattern will be assessed using the Mediterranean Diet Adherence Screener (MEDAS), a validated 14-item questionnaire designed to evaluate compliance with key components of the Mediterranean diet. Each item is scored 0 or 1, depending on whether the dietary criterion is met, yielding a total score ranging from 0 to 14, where higher scores indicate greater adherence to the Mediterranean diet.
Time frame: at the 16th and 34-36th week of gestation
Psychological Distress
The Kessler Psychological Distress Scale (K10) will be used to assess nonspecific psychological distress, including symptoms of anxiety and depression, experienced over the past four weeks. The K10 consists of 10 items, each rated on a 5-point Likert scale ranging from 1 (none of the time) to 5 (all of the time), resulting in a total score between 10 and 50. Higher scores indicate greater psychological distress.
Time frame: at the 16th and 34-36th week of gestation
Erythrocytes
Erythrocyte count (×10⁶ cells/µL), will be measured using an automated Coulter haematology analyser (Brand, City, Country).
Time frame: at 34th week of gestation and at delivery
Lipid profile (in mother and cord blood)
Plasma total, high-density lipoprotein and low-density lipoprotein cholesterol and triglycerides (all in mg/dL) will be assessed using an autoanalyzer.
Time frame: at 34th week of gestation and at delivery
Plasma glucose (in mother and cord blood)
Plasma glucose concentrations will be determined using the glucose oxidase enzymatic colorimetric method.
Time frame: at 34th week of gestation and at delivery
Total plasma antioxidant capacity (in mother and cord blood)
Total plasma antioxidant capacity (in maternal and cord blood) will be measured using a commercial colorimetric assay kit based on spectrophotometry, following the manufacturer's instructions. Results will be expressed in Trolox equivalents (mmol Trolox/L), where higher values indicate greater antioxidant capacity.
Time frame: at 34th week of gestation and at delivery
Antioxidant enzymes activity (in mother and cord blood)
Erythrocyte membrane catalase, glutathione peroxidase, and superoxide dismutase enzyme activities will be measured by spectrophotometry using standard biochemical assays. Results will be expressed in units per milligram of hemoglobin (U/mg Hb), where higher values indicate greater enzymatic antioxidant activity.
Time frame: at 34th week of gestation and at delivery
Pro- and anti-inflammatory signal (in mother and cord blood)
Some maternal and umbilical cord plasma pro-inflammatory and anti-inflammatory cytokines (IL-1β, IL-2, IL-6, IL-8, IL-10, IFN-γ and TNF-α, IL-1ra and TNF Srii α), some adipokines (adiponectin, adipsin, resistin, PAI-active, insulin and leptin) and myokines (irisin) will be measured by the employment of Luminex xMAP technology. Other relevant biomarkers related to bone metabolism (ACTH, DKK-1, FGF-23, Osteocalcin, OPN-Osteopontin, Osteoprotegerin, PTH and SOST) will be measured with Luminex xMAP technology. Each outcome will be reported separately, with concentrations expressed in pg/mL or ng/mL, as appropriate for the specific analyte.
Time frame: at 34th week of gestation and at delivery
Birth weight
Birth weight will be recorded in grams (g).
Time frame: At delivery
Delivery complications
Mode of delivery (vaginal or caesarean section) and any maternal or neonatal complications occurring during delivery will be obtained from hospital medical records and classified according to the attending obstetrician's report.
Time frame: At delivery
Apgar score
Apgar score will be evaluated at 1 and 5 minutes after delivery by trained obstetric or neonatal staff, following standard clinical procedures. Scores range from 0 to 10, with higher values indicating better neonatal condition.
Time frame: At delivery
Polypharmacy
Polypharmacy will be defined as the concurrent use of five or more medications.
Time frame: At delivery and 6 and 12 months postpartum
Resting energy expenditure
Resting energy expenditure is measured in the fasting and fed state by indirect calorimetry
Time frame: at the 16th and 34-36th week of gestation
Haematocrit
Haemoglobin concentration (g/dL) will be measured using an automated Coulter haematology analyser (Brand, City, Country).
Time frame: at 34th week of gestation and at delivery
Platelet count and leukocyte
Platelet count (×10³ cells/µL) and leukocyte count (×10³ cells/µL) will be measured using an automated Coulter haematology analyser (Brand, City, Country).
Time frame: at 34th week of gestation and at delivery
Mean corpuscular volume
Mean corpuscular volume (fL) will be measured using an automated Coulter haematology analyser (Brand, City, Country).
Time frame: at 34th week of gestation and at delivery
Insulin levels (in mother and cord blood)
Plasma insulin levels will be quantified by enzyme-linked immunosorbent assay (ELISA).
Time frame: at 34th week of gestation and at delivery
Glycosylated haemoglobin levels (in mother and cord blood)
Glycosylated haemoglobin (HbA1c) will be determined using the enzymatic colorimetric method.
Time frame: at 34th week of gestation and at delivery
Body length and head circumference
Length in centimeters (cm), and head circumference in centimeters (cm).
Time frame: At delivery
Hospitalization days
Hospitalization will be recorded as the number and duration of inpatient stays.
Time frame: At delivery
Cost-effectiveness analyses
Cost-effectiveness analyses will be conducted based on health service utilization and associated costs extracted from the hospital database. Each outcome will be reported separately, with appropriate units (e.g., number of admissions, days hospitalized, number of medications, EQ-5D-5L index score, euros): Count (episodes, days, or medications), EQ-5D-5L index (score), and euros (€).
Time frame: At delivery and 6 and 12 months postpartum
Placental mitochondrial leak respiration
Mitochondrial oxygen (O₂) flux will be measured in placental tissue using high-resolution respirometry (Oroboros O₂k, Oroboros Instruments, Innsbruck, Austria). Tissue samples will be analyzed in fresh homogenates under controlled substrate-uncoupler-inhibitor titration (SUIT) protocols to evaluate basal, leak, and maximal respiratory states. Oxygen flux will be expressed as picomoles of O₂ consumed per second per milligram of tissue (pmol O₂·s-¹·mg-¹).
Time frame: At delivery
Changes to maternal, placenta and umbilical cord proteome
Changes in proteome will be analyzed using the Olink® proximity extension assay (PEA) technology, following the manufacturer's standardized protocol (Olink Proteomics, Uppsala, Sweden). Protein abundance will be expressed as normalized protein expression (NPX) units, where higher NPX values indicate greater relative protein concentration.
Time frame: At delivery
Plan to share: No — This section provides details of the study plan, including how the study is designed and what the study is measuring.
Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.
Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 27 months is above that.
Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad Pública de Navarra